Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-β signaling

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 4, 2010, Pages 653-661

  Cummins, Timothy D ^a   Barati, Michelle T ^a   Coventry, Susan C ^a   Salyer, Sarah A ^a   Klein, Jon B ^a   Powell, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Fibrosis; Mass spectrometry; Proteomic; TGF signaling; Type 1 diabetes

Indexed keywords

CANNABINOID 1 RECEPTOR; CARNITINE PALMITOYLTRANSFERASE I; DJ 1 PROTEIN; GLUCOKINASE; GLUCOSE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GRB2 RELATED ADAPTOR PROTEIN; INHIBITOR OF DIFFERENTIATION 3; INSULIN RECEPTOR SUBSTRATE 2; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; ISOCITRATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PROTEIN TYROSINE PHOSPHATASE; PYRUVATE KINASE; REGULATOR PROTEIN; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA; TRANSKETOLASE; TUBERIN; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOBLOTTING; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY TUBULE; KIDNEY TUBULE CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY TUBULES; MICE; MODELS, BIOLOGICAL; PROTEOMICS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

MUS;

EID: 76849111483     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.09.029     Document Type: Article

References (81)

1. Molitch M.E., et al. Nephropathy in diabetes. Diabetes Care 27 Suppl. 1 (2004) S79-83
2. Xue J.L., et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. 12 12 (2001) 2753-2758
3. Lewis E.J., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 12 (2001) 851-860
4. Nath K.A. The tubulointerstitium in progressive renal disease. Kidney Int. 54 3 (1998) 992-994
5. Cravatt B.F., Simon G.M., and Yates III J.R. The biological impact of mass-spectrometry-based proteomics. Nature 450 7172 (2007) 991-1000
6. Powell D.W., Merchant M.L., and Link A.J. Discovery of regulatory molecular events and biomarkers using 2D capillary chromatography and mass spectrometry. Expert Rev. Proteomics 3 1 (2006) 63-74
7. Link A.J., et al. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17 7 (1999) 676-682
8. Powell D.W., et al. Cluster analysis of mass spectrometry data reveals a novel component of SAGA. Mol. Cell. Biol. 24 16 (2004) 7249-7259
9. Nesvizhskii A.I., Vitek O., and Aebersold R. Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat. Methods 4 10 (2007) 787-797
10. Liu H., Sadygov R.G., and Yates III J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76 14 (2004) 4193-4201
11. Old W.M., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell Proteomics 4 10 (2005) 1487-1502
12. Cummins T.D., and Powell D.W. Use of quantitative mass spectrometry analysis in kidney research. Semin. Nephrol. 27 6 (2007) 574-583
13. Fleischer T.C., et al. Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev. 20 10 (2006) 1294-1307
14. Burg J.S., et al. Insig regulates HMG-CoA reductase by controlling enzyme phosphorylation in fission yeast. Cell Metab. 8 6 (2008) 522-531
15. Hughes A.L., et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5 2 (2007) 143-149
16. Powell D.W., et al. Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice. Nephron. Exp. Nephrol. 111 1 (2008) e11-e19
17. McAfee K.J., et al. Analyzing proteomes and protein function using graphical comparative analysis of tandem mass spectrometry results. Mol. Cell Proteomics 5 8 (2006) 1497-1513
18. Thongboonkerd V., et al. Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J. Am. Soc. Nephrol. 15 3 (2004) 650-662
19. Khundmiri S.J., et al. Parathyroid hormone regulation of NA+,K+-ATPase requires the PDZ 1 domain of sodium hydrogen exchanger regulatory factor-1 in opossum kidney cells. J. Am. Soc. Nephrol. 16 9 (2005) 2598-2607
20. Gradl D., Kuhl M., and Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell. Biol. 19 8 (1999) 5576-5587
21. Masszi A., et al. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am. J. Pathol. 165 6 (2004) 1955-1967
22. Asuni A.A., et al. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 24 12 (2006) 3387-3392
23. Liang M.H., and Chuang D.M. Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J. Biol. Chem. 281 41 (2006) 30479-30484
24. Takeji M., et al. CCAAT/Enhancer-binding protein delta contributes to myofibroblast transdifferentiation and renal disease progression. J. Am. Soc. Nephrol. 15 9 (2004) 2383-2390
25. Ginsburg B.C., and Lamb R.J. Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison. Behav. Pharmacol. 17 3 (2006) 249-257
26. Begriche K., et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 1 (2006) 1-28
27. Obici S., et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat. Med. 9 6 (2003) 756-761
28. Ishihara H., et al. Inhibition of pancreatic beta-cell glucokinase by antisense RNA expression in transgenic mice: mouse strain-dependent alteration of glucose tolerance. FEBS Lett. 371 3 (1995) 329-332
29. Lehto M., et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia 42 9 (1999) 1131-1137
30. Massa O., et al. High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP). Diabetologia 44 7 (2001) 898-905
31. Postic C., et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274 1 (1999) 305-315
32. Rossetti L., et al. Abnormal regulation of HGP by hyperglycemia in mice with a disrupted glucokinase allele. Am. J. Physiol. 273 4 Pt 1 (1997) E743-750
33. Velho G., et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 40 2 (1997) 217-224
34. Brown L.J., et al. Lethal hypoglycemic ketosis and glyceroluria in mice lacking both the mitochondrial and the cytosolic glycerol phosphate dehydrogenases. J. Biol. Chem. 277 36 (2002) 32899-32904
35. Heikkinen S., et al. Hexokinase II-deficient mice. Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes. J. Biol. Chem. 274 32 (1999) 22517-22523
36. Malkki M., Laakso M., and Deeb S.S. The human hexokinase II gene promoter: functional characterization and detection of variants among patients with NIDDM. Diabetologia 40 12 (1997) 1461-1469
37. Almind K., et al. Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia 42 10 (1999) 1244-1249
38. Dong X., et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 116 1 (2006) 101-114
39. Kubota T., et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107 24 (2003) 3073-3080
40. Kushner J.A., et al. Pdx1 restores beta cell function in Irs2 knockout mice. J. Clin. Invest. 109 9 (2002) 1193-1201
41. Suzuki R., et al. Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice. J. Biol. Chem. 279 24 (2004) 25039-25049
42. Uchida T., et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat. Med. 11 2 (2005) 175-182
43. Batt J., et al. Pituitary, pancreatic and gut neuroendocrine defects in protein tyrosine phosphatase-sigma-deficient mice. Mol. Endocrinol. 16 1 (2002) 155-169
44. Brand I.A., and Heinickel A. Key enzymes of carbohydrate metabolism as targets of the 11.5-kDa Zn(2+)-binding protein (parathymosin). J. Biol. Chem. 266 31 (1991) 20984-20989
45. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8 1 (2002) 75-79
46. Jin F., et al. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc. Natl. Acad. Sci. U. S. A. 93 17 (1996) 9154-9159
47. Frayling T.M. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat. Rev. Genet. 8 9 (2007) 657-662
48. Lau P., et al. The orphan nuclear receptor, RORalpha, regulates gene expression that controls lipid metabolism: staggerer (SG/SG) mice are resistant to diet-induced obesity. J. Biol. Chem. 283 26 (2008) 18411-18421
49. Qiu L.Q., Sinniah R., and Hsu S.I. Coupled induction of iNOS and p53 upregulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgA nephropathy. J. Am. Soc. Nephrol. 15 8 (2004) 2066-2078
50. Clements C.M., et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U. S. A. 103 41 (2006) 15091-15096
51. Bublitz C., and Steavenson S. The pentose phosphate pathway in the endoplasmic reticulum. J. Biol. Chem. 263 26 (1988) 12849-12853
52. Xu Z.P., Wawrousek E.F., and Piatigorsky J. Transketolase haploinsufficiency reduces adipose tissue and female fertility in mice. Mol. Cell. Biol. 22 17 (2002) 6142-6147
53. Gysemans C.A., et al. Dual role of interferon-gamma signalling pathway in sensitivity of pancreatic beta cells to immune destruction. Diabetologia 44 5 (2001) 567-574
54. Suk K., et al. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 166 7 (2001) 4481-4489
55. Russell R.G., et al. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium. Cancer Res. 64 20 (2004) 7220-7225
56. Simbulan-Rosenthal C.M., et al. Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation. Oncogene 24 35 (2005) 5443-5458
57. Bidder M., et al. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J. Biol. Chem. 277 46 (2002) 44485-44496
58. Shoulders C.C. USF1 on trial. Nat. Genet. 36 4 (2004) 322-323
59. Powis G., and Montfort W.R. Properties and biological activities of thioredoxins. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 261-295
60. S. Soundar, M. O'hagan, K.S. Fomulu and R.F. Colman, Identification of Mn2+-binding aspartates from alpha, beta, and gamma subunits of human NAD-dependent isocitrate dehydrogenase, J. Biol. Chem., 281(30):21073-21081.
61. Horejsi V., Zhang W., and Schraven B. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat. Rev. Immunol. 4 8 (2004) 603-616
62. Janssen E., and Zhang W. Adaptor proteins in lymphocyte activation. Curr. Opin. Immunol. 15 3 (2003) 269-276
63. Feng X.H., and Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21 (2005) 659-693
64. Hsu C.Y., et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann. Intern. Med. 141 2 (2004) 95-101
65. Caramori M.L., and Mauer M. Diabetes and nephropathy. Curr. Opin. Nephrol. Hypertens. 12 3 (2003) 273-282
66. Ziyadeh F.N., and Sharma K. Overview: combating diabetic nephropathy. J. Am. Soc. Nephrol. 14 5 (2003) 1355-1357
67. Gilbert R.E., and Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury. Kidney Int. 56 5 (1999) 1627-1637
68. Zheng S., et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53 12 (2004) 3248-3257
69. Kieffer P., et al. Quantitative changes in protein expression of cadmium-exposed poplar plants. Proteomics 8 12 (2008) 2514-2530
70. Diao W.F., et al. Serum, liver, and kidney proteomic analysis for the alloxan-induced type I diabetic mice after insulin gene transfer of naked plasmid through electroporation. Proteomics 6 21 (2006) 5837-5845
71. Kislinger T., et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 125 1 (2006) 173-186
72. Zhao Y., et al. Comprehensive analysis of the mouse renal cortex using two-dimensional HPLC - tandem mass spectrometry. Proteome Sci. 6 (2008) 15
73. Tilton R.G., et al. Diabetes-induced changes in the renal cortical proteome assessed with two-dimensional gel electrophoresis and mass spectrometry. Proteomics 7 10 (2007) 1729-1742
74. Schmid U., et al. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab. Res. Rev. 24 5 (2008) 371-377
75. Li J.H., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 164 4 (2004) 1389-1397
76. Prabhakar S., et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J. Am. Soc. Nephrol. 18 11 (2007) 2945-2952
77. Bottinger E.P., and Bitzer M. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 13 10 (2002) 2600-2610
78. Buday L. Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim. Biophys. Acta 1422 2 (1999) 187-204
79. Feng G.S., et al. Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. J. Biol. Chem. 271 21 (1996) 12129-12132
80. Trub T., et al. The role of a lymphoid-restricted, Grb2-like SH3-SH2-SH3 protein in T cell receptor signaling. J. Biol. Chem. 272 2 (1997) 894-902
81. Ziyadeh F.N. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J. Am. Soc. Nephrol. 15 Suppl. 1 (2004) S55-S57